American Society of Hirudotherapy

Duplicated Antistasin-Like Anticoagulant

Four-domain antistasin-like recombinant anticoagulant from H. medicinalis (Brovina 2026) — inhibits intrinsic + extrinsic + common pathway via aPTT / PT / TT.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Duplicated Antistasin-Like Anticoagulant25 kDa
Molecular weight (kilodaltons) of Duplicated Antistasin-Like Anticoagulant (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

The duplicated antistasin-like protein's in vitro broad coagulation inhibition does NOT establish clinical efficacy. No FDA-approved derivative exists; characterization remains at recombinant expression / clotting-assay stage.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
25,000 Da
Source species
Hirudo medicinalis
Discovered
2026 · Brovina KA et al.

Biological Targets

  • → intrinsic pathway
  • → extrinsic pathway
  • → common pathway

Key Citations

  1. Brovina KA et al. (2026), Biomolecules · PMID 41594695

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.